Panacea Biotec has entered into a tripartite agreement with Natco Pharma and Breckenridge Pharmaceutical Inc. for the manufacture and supply of Azacitidine Injection for the US market under Breckenridge's already-approved ANDA. Azacitidine is a generic equivalent of Vidaza, which is marketed by Celgene Corporation, US.
As per the terms of the agreement, Natco has provided the technology for manufacturing Azacitidine to Panacea Biotec's facility located at Baddi in the state of Himachal Pradesh. Panacea Biotec will be responsible for manufacture and supply of the product, which will be marketed, sold and distributed by Breckenridge in the US.
Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities. It is one of the largest vaccine producers and biotechnology companies in India.
